Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $67.76, for a total value of $135,520.00. Following the completion of the sale, the executive vice president now owns 5,311 shares of the company’s stock, valued at $359,873.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
TNDM traded up $1.67 during midday trading on Friday, reaching $64.52. 1,602,082 shares of the company were exchanged, compared to its average volume of 1,600,719. The company has a quick ratio of 2.13, a current ratio of 2.43 and a debt-to-equity ratio of 0.09. Tandem Diabetes Care Inc has a one year low of $20.08 and a one year high of $74.81. The firm has a market cap of $3.65 billion, a PE ratio of -25.30 and a beta of 0.51. The company’s 50-day simple moving average is $66.65.
Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. The business had revenue of $66.00 million for the quarter, compared to the consensus estimate of $47.55 million. During the same quarter last year, the firm earned ($1.82) EPS. The company’s revenue for the quarter was up 141.9% on a year-over-year basis. Equities analysts expect that Tandem Diabetes Care Inc will post -0.81 EPS for the current year.
A number of analysts recently commented on the company. BidaskClub lowered Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Lake Street Capital reiterated a “buy” rating on shares of Tandem Diabetes Care in a research report on Monday, June 17th. Bank of America reiterated a “neutral” rating and issued a $65.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, May 17th. ValuEngine upgraded Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 15th. Finally, Svb Leerink started coverage on Tandem Diabetes Care in a report on Monday, May 13th. They set an “outperform” rating and a $83.00 target price on the stock. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $68.13.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Story: Key terms to understand channel trading
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.